(3-chloro-2-(trimethylsilyl)phenyl)boronic acid | 1257792-93-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-chloro-2-(trimethylsilyl)phenyl)boronic acid
• 英文别名: (3-Chloro-2-trimethylsilylphenyl)boronic acid；(3-chloro-2-trimethylsilylphenyl)boronic acid
• CAS: 1257792-93-0
• 化学式: C₉H₁₄BClO₂Si
• 分子量: 228.558
• InChiKey: MDDJBNAWIYVEET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.56
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-chloro-2-(trimethylsilyl)phenyl)boronic acid 在 一氯化碘 作用下， 以 氯仿 为溶剂， 反应 6.0h， 以88%的产率得到3-chloro-2-iodophenylboronic acid
  参考文献：
  名称：

  Electrophilic ipso-iodination of silylated arylboronic acids

  摘要：

  Silylated functionalized arylboronic acids were converted into corresponding iodinated arylboronic acids in good yields via the electrophilic ipso-desilylation effected with iodine chloride in refluxing CHCl3. Disilylated arylboronic acids were susceptible to diiodination. In addition, the structural characterization and reactivity of a novel sterically hindered ortho-silylated diarylborinic ester were reported. The potential of selected iodinated phenylboronic acids as monomers for the SuzukieMiyaura cross-coupling polymerization was demonstrated. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2010.08.016
• 作为产物：
  描述：

  间氯溴苯 在 正丁基锂 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.42h， 生成 (3-chloro-2-(trimethylsilyl)phenyl)boronic acid
  参考文献：
  名称：

  SMALL MOLECULE INHIBITORS OF KRAS PROTEINS

  摘要：

  Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

  公开号：

  WO2024103010A1

文献信息

• Electrophilic ipso-iodination of silylated arylboronic acids
  作者：K. Durka、J. Górka、P. Kurach、S. Luliński、J. Serwatowski

  DOI：10.1016/j.jorganchem.2010.08.016

  日期：2010.11

  Silylated functionalized arylboronic acids were converted into corresponding iodinated arylboronic acids in good yields via the electrophilic ipso-desilylation effected with iodine chloride in refluxing CHCl3. Disilylated arylboronic acids were susceptible to diiodination. In addition, the structural characterization and reactivity of a novel sterically hindered ortho-silylated diarylborinic ester were reported. The potential of selected iodinated phenylboronic acids as monomers for the SuzukieMiyaura cross-coupling polymerization was demonstrated. (C) 2010 Elsevier B.V. All rights reserved.
• SMALL MOLECULE INHIBITORS OF KRAS PROTEINS
  申请人：[en]MERCK SHARP & DOHME LLC

  公开号：WO2024103010A1

  公开（公告）日：2024-05-16

  Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.